|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chinese Atherosclerosis Risk Evaluation(CARE II)study:a novel cross-sectional,multicentre study of the prevalence of high-risk atherosclerotic carotid plaque in Chinese patients with ischaemic cerebrovascular events-design and rationale显示文摘Background:Carotid atherosclerotic plaque is identified as one of the main sources of ischaemic stroke.However,the prevalence of carotid high-risk atherosclerotic plaque in Chinese patients with ischaemic cerebrovascular events has been inconsistently reported and needs to be investigated in a large population.Objectives:The primary objective of CARE II study was to determine the prevalence and characteristics of high-risk features of atherosclerotic plaques in the carotid arteries in Chinese patients with recent ischaemic stroke or transient ischaemia attack(TIA).The relationship between carotid plaque features and cerebral infarcts,the differences of carotid plaque patterns among different regions of China and the gender specific characteristics of carotid plaque will be also determined.Study design:The CARE II study will enrol 1000 patients with recent ischaemic stroke or TIA and carotid plaque from 13 hospitals and medical centres across China.In this cross-sectional,non-randomised,observational,multicentre study,all patients will undergo carotid artery MRI of bilateral carotid arteries and routine brain MRI with standardised protocols.The MRI will be interpreted at core reading centres to evaluate the characteristics of morphology and compositions of carotid plaque.Conclusions:This is a cross-sectional,multicentre study to investigate the prevalence and characteristics of high-risk atherosclerotic carotid plaque in Chinese patients with stroke and TIA by using high-resolution MRI of vessel wall.This trial is sufficiently powered to demonstrate the prevalence of carotid high-risk plaque and to explore regional differences in Chinese patients who suffered stroke. | Xihai Zhao Rui Li Daniel S Hippe Thomas S Hatsukami Chun Yuan CARE-II Investigators | 2017 | Stroke & Vascular Neurology2017，2，1： | 21 |
| 2 | D-二聚体预测稳定型冠状动脉性心脏病患者的长期病因特异性死亡率、心血管事件和癌症显示文摘交联纤维蛋白的降解产物D-二聚体是高凝状态和血栓形成事件的标志。D-二聚体水平中度升高与血管疾病患者静脉和动脉事件的风险相关。在缺血性疾病长期普伐他汀干预(long-term intervention with pravastatin in ischemic disease,LIPID)试验中,研究者在存在其他危险因素的背景下,评估了D-二聚体水平在预测长期血管转归、病因特异性死亡率和新发癌症中的作用。 | 刘青 叶鹏 Simes J Robledo KP White HD Espinoza D Stewart RA Sullivan DR Zeller T Hague W Nestel PJ Glasziou PP Keech AC Elliott J Blankenberg S Tonkin AM LIPID study investigators | 2018 | 中华高血压杂志2018，26，3： | 6 |
| 3 | Effectiveness of intravenous r- tPA versus UK for acute ischaemic stroke: a nationwide prospective Chinese registry study显示文摘Background Intravenous recombinant tissue plasminogen activator(r-tPA)and urokinase(UK)are both recommended for the treatment of acute ischaemic stroke(AIS)in China,but with few comparative outcome data being available.We aimed to compare the outcomes of these two thrombolytic agents for the treatment of patients within 4.5 hours of onset of AIS in routine clinical practice in China.Methods A pre-planned,prospective,nationwide,multicentre,real-world registry of consecutive patients with AIS(age≥18 years)who received r-tPA or UK within 4.5 hours of symptom onset according to local decision-making and guideline recommendations during 2017-2019.The primary effectiveness outcome was the proportion of patients with an excellent functional outcome(defined by modified Rankin scale scores 0 to 1)at 90 days.The key safety endpoint was symptomatic intracranial haemorrhage according to standard definitions.Multivariable logistic regression was used for comparative analysis,with adjustment according to propensity scores to ensure balance in baseline characteristics.Results Overall,4130 patients with AIS were registered but 320 had incomplete or missing data,leaving 3810 with available data for analysis of whom 2666 received r-tPA(median dose 0.88(IQR 0.78-0.90)mg/kg)and 1144 received UK(1.71(1.43-2.00)×104 international unit per kilogram).There were several significant intergroup differences in patient characteristics:r-tPA patients were more educated,had less history of stroke,lower systolic blood pressure,greater neurological impairment and shorter treatment times from symptom onset than UK patients.However,in adjusted analysis,the frequency of excellent outcome(OR 1.18,95%CI 1.00 to 1.40,p=0.052)and symptomatic intracranial haemorrhage(OR 0.70,95%CI 0.33 to 1.47,p=0.344)were similar between groups.Conclusions UK may be as effective and carry a similar safety profile as r-tPA in treating mild to moderate AIS within guidelines in China.Registration http://gffzzd5593dd32ed44506hfb9uvfbxp6xv6puq.ffgz.tsg.suse.edu.cn identifier:NCT02854592. | Xinhong Wang Xiaoqiu Li Yuming Xu Runhui Li Qingcheng Yang Yong Zhao Fengyun Wang Baoying Sheng Runqing Wang Shaoyuan Chen Lihua Wang Liying Shen Xiaowen Hou Yu Cui Duolao Wang Bin Peng Craig S Anderson Huisheng Chen On behalf of INTRECIS Investigators | 2021 | Stroke & Vascular Neurology2021，6，4： | 2 |
| 4 | Risk and benefits of estrogen plus progestin in healthy postmenopausal women principal results form the women' s health initiative randomized cotrolled trial显示文摘 | | 2002 | JAMA2002，288，3： | 1 |
| 5 | Emergence of a novel swine-origin influenza A(H1N1) virus in humans显示文摘 | Novel Swine-Origin Influenza A(H1N1) Virus investigation Team Dawood FS Jain S | 2009 | N Engl J Med2009，360，： | 1 |
| 6 | Effect ofrosiglitazone on the frequency of diabetes in patients with impaired glucosetolerance or impaired fasting glucose:a randomised controlled trial显示文摘 | DREAM(Diabetes REduction Assessment with ramipril and rosiglitazoneMedication)Trial Investigators Gerstein HC Yusuf S | 2006 | Lancet2006，368，9541： | 1 |
| 7 | Telmisartan,ramipril,or both in patients at high risk for vascular events显示文摘 | ONTARGET Investigators Yusuf S Teo KK | 2008 | N Engl J Med2008，358，： | 1 |
| 8 | Effect of rosiglitazone on the frequency of diabetes in patients with im- paired glucose tolerance or impaired fasting glucose: a randomised controlled trial显示文摘 | DREAM Trial Investigators Gerstein HC Yusuf S | 2006 | Lancet2006，368，9541： | 1 |
| 9 | Risks and benefits of estrogen plus progesterone in healthy post-menopausal women 显示文摘 | Writing Group for the Women's Health Initiative Investigators | 2002 | JAMA2002，288，3： | 1 |
| 10 | Oral rivaroxaban for symptomatic venous thremboembohsm 显示文摘 | EINSTEIN INVESTIGATOR S BAUERSACHS R BERKOWITZ S D eta/ | 2010 | N Engl J Med2010，363，26： | 1 |
| 11 | Intensive versus conventional glucose control in critically ill patients 显示文摘 | NICE - SUGAR Study Investigators Finfer S Chittock DR | 2009 | N Engl J Med2009，360，13： | 1 |
| 12 | Risks and benefits of estrogen plus progestin in healthy postmenopausal woman: prineiple results from the Woman's Health Initiative randomized eontrolled trial显示文摘 | The Writing Group for the Women's Health Initiative Investigators | 2002 | JAMA2002，288，： | 1 |
| 13 | Telmisartan,ramipril,or both in patients at high risk for vascular events显示文摘 | ONTARGET Investigators Yusuf S Teo KK | 2008 | N Engl J Med2008，358，： | 1 |
| 14 | 显示文摘 | Seth M L Raychaudhuri S P Investigations on the relationship of new brinjal mosaic virus and its vector Aphis gossypii Glov | 1977 | Acta Botanica Indica1977，5，2： | 1 |
| 15 | Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events ( ACTIVE W) : a randomised controlled trial 显示文摘 | ACTIVE Writing Group of the ACTIVE Investigators Connolly S Pogue J Hart R | 2006 | Lancet2006，367，9526： | 1 |
| 16 | Risks and benefits of estrogen plus progestin in healthy postmenopausal women-Principal results from the Women's Health Initiative randomized controlled trial 显示文摘 | Writing Group for the Women 's Health Initiative Investigators | 2002 | JAMA2002，288，： | 1 |
| 17 | Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial 显示文摘 | DREAM ( Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators Gerstein HC Yusuf S | 2006 | Lancet2006，368，9541： | 1 |
| 18 | The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design an baseline characteristics in- cluding a recta-analysis of the effects of thienopyridines in vascular disease显示文摘 | Mehta SR Yusuf S CURE Study Investigators | 2000 | Eur Heart J2000，21，24： | 1 |
| 19 | Dose comparisons of clopidogrel and aspirin in acutecoronary syndromes显示文摘 | CURRENT-OASIS 7 Investigators Mehta SR Bassand JP Chrolav-icius S | 2010 | N Engl J Med2010，363，10： | 1 |
| 20 | Elevated pulse pressure during the acute period of is- chemic stroke is associated with poor stroke outcome显示文摘 | Aslanyan S Weir CJ Lees KR GAIN International Steering Committee and Investigators | 2004 | Stroke2004，35，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员